

# Quantitative bias analysis for outcome phenotype error correction in comparative effect estimation: an empirical evaluation and simulation study (QBA evaluation)

**First published:** 13/04/2023

**Last updated:** 03/07/2023

Study

Ongoing

## Administrative details

### EU PAS number

EUPAS104459

---

### Study ID

105663

---

### DARWIN EU® study

No

---

### Study countries

 United Kingdom

---

### Study description

Outcome phenotype error is acknowledged but rarely corrected for in causal effect estimation studies using observational data. Quantitative bias analysis (QBA) is a method for phenotype error correction, but the extent to which it minimizes bias in effect estimates is unclear. We will empirically evaluate the impact of QBA for outcome phenotype error correction in several pharmacoepidemiologic comparative effect estimation scenarios. Further, we will simulate an analytic space defined by outcome incidence, observed effect estimates, and phenotype measurement errors to determine which QBA input combinations produce valid results.

---


### Study status

Ongoing

## Research institutions and networks

### Institutions

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford

 United Kingdom

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

**Educational Institution**

**Hospital/Clinic/Other health care facility**

## Contact details

### Study institution contact

James Weaver james.weaver@ndorms.ox.ac.uk

Study contact

[james.weaver@ndorms.ox.ac.uk](mailto:james.weaver@ndorms.ox.ac.uk)

### Primary lead investigator

James Weaver

Primary lead investigator

## Study timelines

### Date when funding contract was signed

Planned: 10/06/2021

Actual: 10/06/2021

---

### Study start date

Planned: 03/01/2022

Actual: 03/01/2022

---

### Date of final study report

Planned: 29/12/2023

## Sources of funding

- Other

## More details on funding

## Study protocol

[EUPAS104459\\_protocol.pdf](#) (542 KB)

## Regulatory

### **Was the study required by a regulatory body?**

No

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

### Study type list

#### **Study type:**

Non-interventional study

---

#### **Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

Effectiveness study (incl. comparative)

Other

## **If 'other', further details on the scope of the study**

Observational research methods

### **Main study objective:**

1) Empirically evaluate QBA for outcome phenotype error correction in several pharmacoepidemiologic comparative effect estimation scenarios 2) Simulate an analytic space defined by outcome incidence, observed effect estimates, and phenotype measurement errors to determine which QBA input combinations produce valid results

## Study Design

### **Non-interventional study design**

Cohort

## Population studied

### **Age groups**

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

---

### **Estimated number of subjects**

6000000

## Study design details

## Data analysis plan

Quantitative bias analysis (QBA) provides algebraic adjustment of person counts in an exposure by outcome 2x2 contingency table based on the magnitude of outcome misclassification. We will evaluate the impact of QBA for outcome phenotype error correction in several empirical and simulated comparative effect estimation pharmacoepidemiologic scenarios. We will evaluate QBA performance with several bias correction metrics.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### Data source(s), other

Optum Electronic Health Record United States, Optum Extended Clinformatics United States, IBM Commercial Database United States, IBM Medicaid State-Sponsored Beneficiaries United States, IBM Medicare Supplemental Beneficiaries United States

---

### Data sources (types)

[Administrative healthcare records \(e.g., claims\)](#)

[Electronic healthcare records \(EHR\)](#)

## Use of a Common Data Model (CDM)

## **CDM mapping**

No

## Data quality specifications

### **Check conformance**

Unknown

---

### **Check completeness**

Unknown

---

### **Check stability**

Unknown

---

### **Check logical consistency**

Unknown

## Data characterisation

### **Data characterisation conducted**

No